Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 13 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

• Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-respondersActive, not recruitingNCT04729322Phase 2Report a problem
• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsTerminatedNCT04725331Phase 1/2Report a problem
• JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid TumorsCompletedNCT04720976Phase 1/2Report a problem
• OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OCActive, not recruitingNCT04713514Phase 2Report a problem
• A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable MelanomaActive, not recruitingNCT04708418Phase 2Report a problem
• Cryoablation With Pembrolizumab Or Avelumab In Urothelial CarcinomaCompletedNCT04701918Phase 2Report a problem
• Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)CompletedNCT04700072Phase 1/2Report a problem
• The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04699123Phase 2Report a problem
• Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic MalignancyCompletedNCT04694781Phase 1Report a problem
• A Study of PY314 in Subjects With Advanced Solid TumorsTerminatedNCT04691375Phase 1Report a problem
• A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsTerminatedNCT04682431Phase 1Report a problem
• Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With PembrolizumabWithdrawnNCT04677361Early Phase 1Report a problem
• Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)Active, not recruitingNCT04675333Phase 2Report a problem
• Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)Active, not recruitingNCT04675294Phase 2Report a problem
• A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT04670679Phase 1Report a problem
• CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsActive, not recruitingNCT04660929Phase 1Report a problem
• NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory CancerCompletedNCT04659629Phase 1Report a problem
• A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaActive, not recruitingNCT04657991Phase 3Report a problem
• GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or PembrolizumabActive, not recruitingNCT04652076Phase 1/2Report a problem
• FS120 Phase 1/1b Study in Patients With Advanced MalignanciesTerminatedNCT04648202Phase 1Report a problem
• Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell CarcinomaStatus unknownNCT04644432Phase 2Report a problem
• Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04638582Phase 2Report a problem
• Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast CancerStatus unknownNCT04634747Phase 2Report a problem
• Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)CompletedNCT04626518Phase 1/2Report a problem
• Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)CompletedNCT04626479Phase 1/2Report a problem
• Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaTerminatedNCT04624113Phase 1Report a problem
• Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)Active, not recruitingNCT04622007Phase 2Report a problem
• In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsActive, not recruitingNCT04616248Phase 1Report a problem
• Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic CancersWithdrawnNCT04611139Phase 1Report a problem
• Study of SNX281 in Subjects With Advanced Solid Tumors and LymphomaTerminatedNCT04609579Phase 1Report a problem
• Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)Active, not recruitingNCT04592653Phase 1/2Report a problem
• Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLCStatus unknownNCT04586465Phase 2Report a problem
• Study to Evaluate D-1553 in Subjects With Solid TumorsActive, not recruitingNCT04585035Phase 1/2Report a problem
• Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of MelanomaCompletedNCT04581382Early Phase 1Report a problem
• Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid TumorsStatus unknownNCT04571632Phase 2Report a problem
• First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid TumorsTerminatedNCT04564417Phase 1Report a problem
• Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesActive, not recruitingNCT04561362Phase 1/2Report a problem
• PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %Active, not recruitingNCT04547504Phase 3Report a problem
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of PembrolizumabWithdrawnNCT04536922Phase 2Report a problem
• A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1Active, not recruitingNCT04534205Phase 2/3Report a problem
• Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)Active, not recruitingNCT04526691Phase 1Report a problem
• Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid MalignanciesActive, not recruitingNCT04521413Phase 1/2Report a problem
• Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)Active, not recruitingNCT04520711Phase 1Report a problem
• Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) SubjectsTerminatedNCT04515979Phase 2Report a problem
• A Safety Study of YQ23 in Advanced Solid Tumors PatientsTerminatedNCT04513067Phase 1Report a problem
• TTX-080 HLA-G Antagonist in Subjects With Advanced CancersActive, not recruitingNCT04485013Phase 1Report a problem
• B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsActive, not recruitingNCT04483778Phase 1Report a problem
• ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT04471974Phase 2Report a problem
• A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid TumorsStatus unknownNCT04460456Phase 1Report a problem
• Hemopurifier Plus Pembrolizumab in Head and Neck CancerTerminatedNCT04453046Not applicableReport a problem
• A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid TumorsCompletedNCT04452214Phase 1Report a problem
• Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)Active, not recruitingNCT04443348Phase 2Report a problem
• AN0025 and Pembrolizumab Combination in Advanced Solid TumorsActive, not recruitingNCT04432857Phase 1Report a problem
• Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast CancerWithdrawnNCT04418219Phase 1/2Report a problem
• SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck CancerWithdrawnNCT04408898Phase 2Report a problem
• Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinCompletedNCT04387461Phase 2Report a problem
• Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingNCT04387084Phase 1Report a problem
• OH2 Injection in Solid TumorsCompletedNCT04386967Phase 1/2Report a problem
• Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Active, not recruitingNCT04379596Phase 2Report a problem
• Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid TumorsCompletedNCT04374877Phase 1Report a problem
• Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)CompletedNCT04373265Phase 1Report a problem
• RTX-240 Monotherapy and in Combination With PembrolizumabTerminatedNCT04372706Phase 1/2Report a problem
• Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.CompletedNCT04358237Phase 1/2Report a problem
• COM902 (A TIGIT Inhibitor) in Subjects With Advanced MalignanciesCompletedNCT04354246Phase 1Report a problem
• Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid TumorsTerminatedNCT04348916Phase 1Report a problem
• Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsCompletedNCT04344795Phase 1Report a problem
• Study of SRF617 in Patients With Advanced Solid TumorsCompletedNCT04336098Phase 1Report a problem
• NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBCActive, not recruitingNCT04335669Phase 3Report a problem
• Analysis of Gut Microbiota in Patients With Brain Metastasis of Non-small Cell Lung Cancer Treated by Pembrolizumab Combined With ChemotherapyStatus unknownNCT04333004Phase 1/2Report a problem
• An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid TumorsActive, not recruitingNCT04305795Phase 1/2Report a problem
• Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)CompletedNCT04305054Phase 1/2Report a problem
• Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid TumorsTerminatedNCT04301011Phase 1Report a problem
• Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid TumorsActive, not recruitingNCT04294576Phase 1Report a problem
• A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCLWithdrawnNCT04279938Phase 1Report a problem
• A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) ExpressionTerminatedNCT04274907Phase 1Report a problem
• Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With PembrolizumabSuspendedNCT04266730Phase 1Report a problem
• KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLCTerminatedNCT04265534Phase 2Report a problem
• Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsActive, not recruitingNCT04262466Phase 1/2Report a problem
• Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCCCompletedNCT04260126Phase 2Report a problem
• A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid MalignanciesTerminatedNCT04244552Phase 1Report a problem
• First-in-Human Study of ICT01 in Patients With Advanced CancerActive, not recruitingNCT04243499Phase 1/2Report a problem
• Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade GliomaWithdrawnNCT04220892Early Phase 1Report a problem
• ENB003 Plus Pembrolizumab Phase 1b/2a in Solid TumorsActive, not recruitingNCT04205227Phase 1/2Report a problem
• Pembrolizumab + Defactinib In Pleural MesotheliomaWithdrawnNCT04201145Phase 1Report a problem
• Pembrolizumab With Axitinib in Recurrent Endometrial CancerWithdrawnNCT04197219Phase 2Report a problem
• Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingNCT04185883Phase 1Report a problem
• A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other CancersCompletedNCT04180215Phase 1/2Report a problem
• Plasma-Adapted First-Line Pembro In NSCLCActive, not recruitingNCT04166487Phase 2Report a problem
• A Study of LY3200882 and Pembrolizumab in Participants With Advanced CancerWithdrawnNCT04158700Phase 1/2Report a problem
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCActive, not recruitingNCT04140526Phase 1/2Report a problem
• Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic MalignancyCompletedNCT04130542Phase 1Report a problem
• Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabActive, not recruitingNCT04130516Phase 1/2Report a problem
• NovoTTF-200A + Pembrolizumab In Melanoma Brain MetastasisWithdrawnNCT04129515Phase 1/2Report a problem
• Study of AMV564 in Subjects With Advanced Solid TumorsStatus unknownNCT04128423Phase 1Report a problem
• Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated PatientsActive, not recruitingNCT04121455Phase 1/2Report a problem
• Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal CancerWithdrawnNCT04119830Phase 2Report a problem
• Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.Status unknownNCT04116775Phase 2Report a problem
• Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid TumorsTerminatedNCT04116320Phase 1Report a problem
• A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)CompletedNCT04105335Phase 1Report a problem
• Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the DrugCompletedNCT04095273Phase 1Report a problem

← Pembrolizumab